RT Journal Article
SR Electronic
T1 An interactive COVID-19 virus Mutation Tracker (CovMT) with a particular focus on critical mutations in the Receptor Binding Domain (RBD) region of the Spike protein
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.22.21249716
DO 10.1101/2021.01.22.21249716
A1 Intikhab Alam
A1 Aleksandar Radovanovic
A1 Roberto Incitti
A1 Allan Kamau
A1 Muhammad Alarawi
A1 Esam I. Azhar
A1 Takashi Gojobori
YR 2021
UL http://medrxiv.org/content/early/2021/01/25/2021.01.22.21249716.abstract
AB Almost one year has passed since the appearance of SARS-CoV-2, causing the COVID-19 pandemic. The number of confirmed SARS-Cov-2 cases worldwide has now reached ∼92 million, with 2 million reported deaths (https://covid19.who.int). Nearly 400,000 SARS-Cov-2 genomes were sequenced from COVID-19 samples and added to public resources such as GISAID (https://gisaid.org). With the vaccines becoming available or entering trials (https://covid19.trackvaccines.org), it is vital to keep track of mutations in the genome of SARS-CoV-2, especially in the Spike protein’s Receptor Binding Domain (RBD) region, which could have a potential impact on disease severity and treatment strategies.1–3 In the wake of a recent increase in cases with a potentially more infective RBD mutation (N501Y) in the United Kingdom, countries worldwide are concerned about the spread of this or similar variants. Impressive sampling and timely increase in sequencing efforts related to COVID-19 in the United Kingdom (UK) helped detect and monitor the spread of the new N501Y variant. Similar sequencing efforts are needed in other countries for timely tracking of this or different variants. To track geographic sequencing efforts and mutations, with a particular focus on RBD region of the Spike protein, we present our daily updated COVID-19 virus Mutation Tracker system, see https://www.cbrc.kaust.edu.sa/covmt.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by King Abdulaziz City of Science and Technology (KACST) grant for COVID-19 research, number 0004-002-01-20-5.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll SARS-CoV-2 isolate sequence data are obtained from GISAID (gisaid.org) and our daily updated mutation tracking analysis is available at CovMT website: https://www.cbrc.kaust.edu.sa/covmt https://www.cbrc.kaust.edu.sa/covmt